Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

TORONTO--(BUSINESS WIRE) March 13, 2024 --Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the“Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials